Companies › Eli Lilly › R&D expense
Eli Lilly research and development expense, 2008–2025
Eli Lilly reported research and development expense of $13.3 billion for the fiscal year ended Dec. 31, 2025, up 21.3% from $11.0 billion the year before, according to its Form 10-K.
Fiscal years labeled by the year in which they ended. Bars drawn from the table below.
Eli Lilly research and development expense by fiscal year
| Fiscal year ended | R&D expense | Change | Filing |
|---|---|---|---|
| Dec. 31, 2025 | $13.3B | +21.3% | 10-K (2026) ↗ |
| Dec. 31, 2024 | $11.0B | +18.0% | 10-K (2026) ↗ |
| Dec. 31, 2023 | $9.31B | +29.5% | 10-K (2026) ↗ |
| Dec. 31, 2022 | $7.19B | +3.8% | 10-K (2023) ↗ |
| Dec. 31, 2021 | $6.93B | +16.0% | 10-K (2023) ↗ |
| Dec. 31, 2020 | $5.98B | +6.8% | 10-K (2023) ↗ |
| Dec. 31, 2019 | $5.59B | +10.8% | 10-K (2022) ↗ |
| Dec. 31, 2018 | $5.05B | −0.9% | 10-K (2021) ↗ |
| Dec. 31, 2017 | $5.10B | −4.0% | 10-K (2020) ↗ |
| Dec. 31, 2016 | $5.31B | +10.7% | 10-K (2019) ↗ |
| Dec. 31, 2015 | $4.80B | +1.3% | 10-K (2018) ↗ |
| Dec. 31, 2014 | $4.73B | −14.4% | 10-K (2017) ↗ |
| Dec. 31, 2013 | $5.53B | +4.8% | 10-K (2016) ↗ |
| Dec. 31, 2012 | $5.28B | +5.1% | 10-K (2015) ↗ |
| Dec. 31, 2011 | $5.02B | +2.8% | 10-K (2014) ↗ |
| Dec. 31, 2010 | $4.88B | +12.9% | 10-K (2013) ↗ |
| Dec. 31, 2009 | $4.33B | +12.6% | 10-K (2012) ↗ |
| Dec. 31, 2008 | $3.84B | — | 10-K (2011) ↗ |
Other Eli Lilly financials
RevenueNet incomeDiluted EPSOperating cash flowDividends per shareDiluted sharesTotal assetsCash and equivalentsStockholders' equity Quarterly results and next earnings date Eli Lilly company hub
FAQ
Q What was Eli Lilly's research and development expense in its latest fiscal year?
A Eli Lilly reported research and development expense of $13.3 billion for the fiscal year ended Dec. 31, 2025, up 21.3% from $11.0 billion the year before, according to its Form 10-K.
Q What is Eli Lilly's highest annual research and development expense on record here?
A $13.3 billion, in the fiscal year ended Dec. 31, 2025, among the fiscal years 2008–2025 reported in its 10-K XBRL data.
Q Where does this research and development expense data come from?
A From Eli Lilly's annual reports on Form 10-K, as tagged in XBRL and published by the SEC (company facts). Research and development expense as reported in the income statement.
Source: Eli Lilly's annual reports on Form 10-K via SEC XBRL company facts, updated Oct. 15, 2026. Research and development expense as reported in the income statement. For each year the most recent 10-K that reports it is used, so a figure a company later restated shows the restated value; the filing link shows which report it came from. Change is our arithmetic. Financial data, not investment advice.